|[July 17, 2014]
Research and Markets: OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/5bdjm5/opportunityanalyze)
has announced the addition of the "OpportunityAnalyzer:
Dengue Vaccines - Opportunity Analysis and Forecasts to 2020"
report to their offering.
Individuals infected with DENV can present with a wide spectrum of
symptoms, including fevers, retro-orbital pain, severe headache, muscle
and joint pain, and rash. The severity of dengue fever ranges from
asymptomatic cases, to classic dengue fever, and to dengue hemorrhagic
fever (DHF) or dengue shock syndrome (DSS) that have a mortality rate of
5%-15%. Because there are no marketed dengue-specific vaccines or
therapeutics, current treatment strategies are limited to supportive
care for those already infected with the virus, and vector control to
reduce DENV transmission.
The near-universal failure of these measures to curtain transmission and
reduce disease burden across te global marketplace - which for the
purposes of this report is comprised of Brazil, India, Mexico,
Singapore, and Thailand - has further enhanced the need for safe and
effective vaccines. GlobalData expects the launch of the first dengue
vaccines, led by Sanofi Pasteur's CYD-TDV and Takeda's DENVax, to
revolutionize the treatment and prevention paradigm.
The dengue vaccine market in Brazil, India, Mexico, Singapore, and
Thailand to grow from $69.6m in 2015 to $398.6m in 2020, at a compound
annual growth rate (CAGR) of 41.8%. This rapid growth will be due to
the expected incorporation of newly-launched dengue vaccines into
routine immunization programs.
KOLs interviewed by GlobalData expect the live-attenuated dengue
vaccines - led by Sanofi Pasteur's CTD-TDV and Takeda's DENVax - to
dominate the marketplace for the duration of the forecast period.
GlobalData anticipates that firms will increasingly turn to innovative
R&D strategies, in particular the exploration of alternative
approaches to early-stage clinical trial design - such as the dengue
human infection model (DHIM) - in order to increase developmental
efficiency, minimize upfront risk, and gain a competitive advantage
Domestically-supplied vaccines, most notably Butantan Institute's
TV-003 in Brazil and Panacea Biotech's/Biological E's TV-003 in India,
are projected to limit market growth due to their low price relative
to vaccines produced by privately-held foreign companies.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
5 Current Surveillance, Prevention, and Control Measures
6 Unmet Needs Assessment and Opportunity Analysis
7 Research and Development Strategies
8 Pipeline Assessment
9 Pipeline Valuation Analysis
For more information visit http://www.researchandmarkets.com/research/5bdjm5/opportunityanalyze
[ InfoTech Spotlight's Homepage ]